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Background: Rheumatic diseases in children are associated with significant morbidity and poor health-related
quality of life (HRQOL). There is no health-related quality of life (HRQOL) scale available specifically for children with less
common rheumatic diseases. These diseases share several features with systemic lupus erythematosus (SLE) such as
their chronic episodic nature, multi-systemic involvement, and the need for immunosuppressive medications. HRQOL
scale developed for pediatric SLE will likely be applicable to children with systemic inflammatory diseases.
Findings: We adapted Simple Measure of Impact of Lupus Erythematosus in Youngsters (SMILEY©) to Simple
Measure of Impact of Illness in Youngsters (SMILY©-Illness) and had it reviewed by pediatric rheumatologists for its
appropriateness and cultural suitability. We tested SMILY©-Illness in patients with inflammatory rheumatic diseases
and then translated it into 28 languages.
Nineteen children (79% female, n=15) and 17 parents participated. The mean age was 12±4 years, with median disease
duration of 21 months (1-172 months). We translated SMILY©-Illness into the following 28 languages: Danish, Dutch,
French (France), English (UK), German (Germany), German (Austria), German (Switzerland), Hebrew, Italian, Portuguese
(Brazil), Slovene, Spanish (USA and Puerto Rico), Spanish (Spain), Spanish (Argentina), Spanish (Mexico), Spanish
(Venezuela), Turkish, Afrikaans, Arabic (Saudi Arabia), Arabic (Egypt), Czech, Greek, Hindi, Hungarian, Japanese,
Romanian, Serbian and Xhosa.
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Conclusion: SMILY©-Illness is a brief, easy to administer and score HRQOL scale for children with systemic rheumatic
diseases. It is suitable for use across different age groups and literacy levels. SMILY©-Illness with its available translations
may be used as useful adjuncts to clinical practice and research.Findings
Introduction
In children, chronic rheumatic diseases are associated with
significant disease- and treatment-related morbidity, thus
impacting their health-related quality of life (HRQOL).
There are generic scales available to assess HRQOL in
children with rheumatic diseases such as the Pediatric
Quality of Life Inventory (PedsQL)-Rheumatology module
[1]. But there is no specific health-related quality of life
(HRQOL) scale that addresses the impact of the less
common rheumatic diseases such as mixed connective
tissue disease (MCTD), juvenile dermatomyositis (JDM),
systemic sclerosis (SS), Sjögren’s syndrome, vasculitides,
Behçets, sarcoidosis or systemic arthritis (SJIA).
Simple Measure of the Impact of Lupus Erythematosus
in Youngsters©" (SMILEY) is valid in US-English [2] and
in Portuguese-for Brazil [3]. SMILEY-US English was
validated through a multicenter study in the US [2].
Subjects with SLE completed other gold standards and
SLE status measures and psychometric properties were
determined [2]. Relationship of HRQOL and changes in
disease activity were measured over time [4]. SMILEY
US English was further translated and adapted into
several languages [2,5,6].Hypothesis
Systemic Lupus Erythematosus (SLE) and systemic inflam-
matory diseases share several features such as their
chronic episodic nature, multi-systemic involvement, and
the need for immunosuppressive medications. HRQOL
scale developed for pediatric SLE will be applicable to chil-
dren with systemic inflammatory diseases. We decided
to adapt a tool that is valid in SLE, titled, SMILEY [2].
We will report the: (i) adaptation of SMILEY© to
Simple Measure of Impact of Illness in Youngsters
(SMILY©-Illness) for use in children with systemic
inflammatory diseases such as MCTD, JDM, SS, Sjögren’s
syndrome, vasculitis and SJIA and preliminary testing in
patients; and (ii) translation into different languages. We
think this is very important since the systemic rheumatic
diseases mentioned above can lead to significant disability
which impact HRQOL.Methods used
Overview in brief
(i) We adapted SMILEY to SMILY©-Illness and had it
reviewed by pediatric rheumatologists from two centers(RWJMS, HSS) for its appropriateness and cultural suit-
ability, and tested SMILY©-Illness in as small sample.
We examined time taken to complete questionnaire,
feasibility, and also collected demographic and disease-
related data. We subsequently translated it into the
following 28 languages using professional translators:
Danish, Dutch, French (France), English (UK), German
(Germany), German (Austria), German (Switzerland),
Hebrew, Italian, Portuguese(Brazil), Slovene, Spanish (USA
and Puerto Rico), Spanish (Spain), Spanish (Argentina),
Spanish (Mexico), Spanish (Venezuela ), Turkish, Afrikaans,
Arabic (Saudi Arabia), Arabic (Egypt), Czech, Greek, Hindi,
Hungarian, Japanese, Romanian, Serbian and Xhosa. Each
translation was reviewed by the pediatric rheumatologist(s)
from that country for its applicability and cultural suitability
in order to be approved.Subjects and settings
Children ≤18 years of age diagnosed with the following
systemic chronic rheumatic diseases were included:
MCTD, JDM, Sjögren’s syndrome, Systemic sclerosis/
CREST, Behçets, sarcoidosis and SJIA. The patients who
had to have been followed for at least one month, and
able to participate in the study as determined by the
pediatric rheumatologist, and their parents (or guardians)
were recruited from two US pediatric rheumatology
practicesa. Children were excluded if they were unable to
complete the questionnaires, or had a significant co-morbid
condition likely to impact HRQOL exclusive of their
rheumatic disease (such as an infectious, endocrine,
psychiatric, congenital, genetic, neurodegenerative or an
oncological process).Measures used
The 26-item SMILY©-Illness for children <19 years fea-
tures parallel child self reports and parent reports with
responses in the form of a five-step scale with different
facial expressions with 5th grade reading level. The four
domains are similar to that of SMILEY and are: Effect
on self (5 items), Limitations (8 items), Social (4 items)
and Burden of Illness (7 items). Scoring is also similar to
SMILEY, where each item score ranges from 1 to 5 and
the total score is transformed to a 1 to 100 scale. Higher
scores indicate better HRQOL. If >12 questions are not
answered, the SMILY©-Illness cannot be scored. The
first two items on current illness status and HRQOL
assessment are not included in the domains or calculating
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ent to the previous month.
Additional data
We examined self-esteem using the Piers Harris Self
concept scale (SCS) [7,8], entitled, “The Way I Feel About
Myself.” Average scores usually range from 46–60 with
higher scores corresponding to better self-concept. We
collected data on demographics, ethnicity, co-morbidity,
insurance, education; and impact of disease using the
PedsQL-Family information form. We recorded the date
of disease onset, and the current/prior use of all medica-
tion(s). The Hollingshead Socioeconomic scale (SES)
score, which takes into account the educational and
occupational status of the family members, was calculated
using the educational and occupational status of the
parents [9]. The scores range from 8 to 66, with higher
scores indicating a higher socioeconomic status [9].
Procedure
Appropriate Institutional Review Board approval was
obtained at both sites. Potential subjects were identified at
each center through the clinic appointment schedule
or during in-patient admissions. Children and parents
completed corresponding versions of the 26-item SMILY©-
Illness and the SCS. The investigator was available at all
times to respond to queries posed by study respondents.
Methods and statistical analysis
Using the SPSS statistical package for Windows (SPSS Inc,
Chicago, Illinois versions 20), we performed descriptive
analyses on all variables and examined data distribution,
and examined instrument scores for ceiling and floor
effects. Minimal missing data were handled in accordance
with rules for scoring each questionnaire. Feasibility was
determined from the percentage of missing values for
each item and the distribution of item responses [10].
Spearman’s rho correlation was used.
Results
Nineteen children (79% female, n=15) and 17 parents
(16 mothers) participated in the study. The mean age
was 12±4 years (3–18 years) with median disease duration
of 21 months (1–172 months), and mean self -concept of
50±8 (36–69). Hollingshead socioeconomic score was
47±11 (26–61). Subjects had the following diagnosis:
SJIA (n=5, 26%), dermatomyositis (n=4, 21%), systemic
sclerosis/CREST syndrome (n=5, 26%), mixed connective
tissue disease (n=2, 11%), Behçet’s disease (n=1, 5%),
sarcoidosis (n=1, 5%), and Sjögren’s syndrome (n=1, 5%).
Seventeen patients used the English translation and two
patients used the Spanish translation. They were of the
following ethnicities: White (n=9, 47%), Black (n=3, 16%),
Mexican/Latino (n=6, 32%), and Asian (n=1, 5%). Thefollowing had major life events (injury/illness-2, change of
job-1, unable to pay bills-1, >/=2 events −4). Six children
were in preschool-5th grade, 11 from 6th grade –11th grade
and 1 was in college. They had the following insurance
to cover their standard clinical care: private (n=12,
63%), Medicaid (n=5, 26%), and other (n=1). The subjects
were either currently using the following medications
or discontinued them: corticosteroids (14/19, 74%),
mycophoenolate mofetil (2/19, 11%), cyclosporine (5/19,
26%), cyclophosphamide and/or rituximab (3/19, 16%),
hydroxychloroquine (9/19, 47%), azathioprine (1/19),
methotrexate (4/19, 21%), and thalidomide (1/19).
Seventeen parents stated that their child had a health
condition. Fourteen patients had an emergency room/
urgent care visit in the last year. Parents reported a
mean of 2.5 ±4, median 2.5 missed work-days in the
past 30 days. Parents perceived the impact of child’s
illness on daily routine at work (sometimes, often or
almost always) in 10/14 cases, and ability to concentrate at
work (sometimes, often or almost always) in 12/14 cases).
The conditions (other than rheumatic diseases) mentioned
by the subjects were: neurocardiogenic syncope (n=1), and
celiac disease (n=1).
Child and parent SMILY scores were highly correlated
(Spearman rho 0.7, p <0.05, n=17). Child SMILY score
correlated with duration illness (Spearman rho =0.4, NS).
We examined the HRQOL scores of patients who had ever
used disease modifying anti-rheumatic drugs (DMARDS)
versus those had never used DMARDS. The mean SMILY
scores were 71±49 (child, n=15) and 66±15 (parent, n=12)
for those had had ever used DMARDS. The mean SMILY
scores were 49±13 (child, n=2) and 53±20 (parent) for
those had had ever used DMARDS.
Feasibility
17 child and 15 parent subjects completed the corre-
sponding reports of SMILY©-illness. Subjects completed
SMILY©-Illness in ≤10 minutes and scoring each ques-
tionnaire took ≤ 10 minutes. For the child report of
SMILY©-Illness, 5 items were omitted out of a total of
442 items (26 items × 17 children) with mean number
of items omitted =0.3±0.7 (range 0–2). Two children did
not complete any forms. For the parent report of
SMILY©-Illness, 19 items were omitted out of a total of
390 items (26 items × 15 parents who completed the scale).
Mean number of items omitted =1.3±2.4 (range 0–8).
Maximum number omitted was 8 items by one parent.
Means, standard deviations and response range of
SMILY©-Illness and other questionnaires
Scores and distribution of SMILY©-Illness, are provided
in Table 1. All the reviewers of SMILY©-Illness approved
the content, found it to be valid and relevant, easy to
understand and especially liked the responses in the
Table 1 Scale descriptives for child and parent reports of
measures of SMILY-Illness
Questionnaire Child report Parent report
SMILY©-illness total 69 ± 17 (40–100) (17) 64 ± 16 (40–100) (15)
Effect on self 68 ± 19 (40–100) (17) 64 ± 16 (40–100) (15)
Limitations 67 ± 17 (40–100) (17) 60 ± 17 (40–100) (15)
Social 81 ± 21 (35–100) (17) 77 ± 21 (40–100) (14)
Burden of illness 64 ± 20 (31–100) (17) 61 ± 18 (30–100) (15)
Global HRQOL 80 ± 22 (40–100) (17) 70 ± 20 (40–100) (14)
Global illness status 71 ± 25 (40–100) (17) 70 ± 22 (40–100) (35)
Mean ± SD (range) (number of subjects) is listed above for child and parent
reports. SMILY©-Illness scores range between 0–100; Abbreviations used:
Simple Measure of Impact of Illness in Youngsters©-illness (SMILY©-Illness);
SD (standard deviation).
Table 2 Translation and adaptation for cultural suitability of
Language SMILY ©
was adapted into
Modified by professional translation
and collaborators who made more
1 Afrikans Prof trans (1 Peds Rheum)
2 Arabic-Egypt Prof trans, 3 Peds Rheum
3 Arabic-Saudi Arabia Prof trans, 1 Peds Rheum
4 Czech Prof trans, 1 Peds Rheum
5 Danish Prof trans, 2 Peds Rheum
6 Dutch Prof trans
7 English-United Kingdom Adaptation by Peds Nephrologist
8 French Prof trans, 1 Peds Rheum
9 German-Austria Prof trans
10 German-Germany Prof trans 1 Peds Rheum
11 German-Swiss Prof Trans 1 Peds Rheum
12 Greek Prof trans, 1 Peds Rheum
13 Hebrew Prof trans
14 Hindi Prof trans,
15 Hungarian Prof trans,
16 Italian Prof trans, 1 Peds Rheum
17 Japanese Prof trans,
18 Portuguese Prof trans 6 Peds Rheum
19 Romanian Prof trans, 1 peds Rheum
20 Serbia Prof trans, 1 Peds Rheum
21 Slovenia Prof trans,
22 Spanish-Argentina Prof trans, 1 Peds Rheum
23 Spanish-Mexican Prof trans, 2 Peds Rheum
24 Spanish-Spain Prof trans, 2 Peds Rheum
25 Spanish –US& Puertorico Prof trans
26 Spanish-Venezuela Prof trans, 2 Peds Rheum
27 Turkish Prof trans, 1 Peds Rheum
28 Xhosa Prof Trans, 1 Peds Rheum nurse
*A physician of Argentinian origin, now living in USA, was involved in both versions
Abbreviations used: Prof trans-Professional translation company. AP- Assistant Professor o
The enclosed translations are in the same order as above.
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validity (Table 2). Due to small sample size we did not
perform calculation for psychometric properties.
Translation process
We had already described the rigorous translation process
of SMILEY in previous manuscripts [5,6]. All the SMILEY
translations were adapted to SMILY©-Illness using a pro-
fessional translation company. Collaborative relationships
with the different centers across the world were already
set up. The review process was similar to the process we
followed for SMILEY translations [5,6]. From each coun-
try, pediatric rheumatologists reviewed the translation and
approved them for content and cultural appropriateness
for their population. Table 2 details the entire adaptationUS English SMILY-Illness
company
edits
Number of reviewers for accuracy and cultural
suitability and have finally approved the translation
1Prof trans (1 Peds Rheum)
3 (3 Peds Rheum)
1 (1 Peds Rheum)
2 (2 Peds Rheum.)
2 (2 Peds Rheum.)
1 (1 Peds Rheum)
1 (Peds Nephrologist)
2 (2 Peds Rheum)
2 (2 Peds Rheum)
2 (2 Peds Rheum)
2 (2 Peds Rheum)
2 (2 Peds Rheum)
1 (Peds Rheum)
1 (1 Peds Rheum)
1 (1 Peds Rheum)
8 (8 Peds Rheum)
2 (2 Peds Rheum)
10 (10 Peds Rheum)
1 (1 Peds Rheum)
1 (1 Peds Rheum)
1 (1 Peds Rheum)
2 (1 Peds Rheum)*
2 (2 Peds Rheum)
2 (2 Peds Rheum)
3 (3 Peds Rheum)*
2 (1 Adult Rheum, 1 Peds Rheum)
3 (3 Peds Rheum)
2 (1 Prof trans, 1 Peds Rheum nurse)
.
f Pediatric Rheumatology, Peds- Pediatrician, Peds Rheum- Pediatric Rheumatologist.
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enclosed at the end of this brief report as Additional file 1.
Conclusion
SMILY©-Illness is a brief, easy to administer and score
HRQOL scale for children with systemic rheumatic dis-
eases. SMILY©-Illness is suitable for use across different
age groups and literacy levels. SMILY©-Illness has good
face and content validity based on its process of adapta-
tion, review by multiple pediatric rheumatologists and
initial testing. However, further validation in each country
is required for the translated and adapted versions. In
our population, a significant percentage of children were
on immunosuppressive/immunomodulatory medications.
Parents appeared to feel the impact of their child’s illness
on a daily basis. The children’s self-concept was only aver-
age. The mean total SMILY illness scores were similar in
the range of what we found for SMILEY scores in patients
with SLE [2]. The lowest scores were found in the domain
of “burden of illness” and the highest score indicating
better HRQOL was found in the social domain as reported
in other studies [2]. As found in the literature, children had
higher scores compared to parents [2].
The number of subjects is very small and it would be
ideal if the disease types were well distributed. Unfortu-
nately in this sample they are not due to referral bias at
the time of the study. Due to the small sample size, we
cannot make any definitive conclusions regarding the
correlations. Another limitation is that we do not have
information regarding the duration of disease prior to
diagnosis.
The availability of translations will make recruitment for
validation easier since these diseases are rare. SMILY©-Ill-
ness with its available translations may be used as useful
adjuncts to clinical practice and research, providing valu-
able insight to the impact of disease on the overall
HRQOL of the child.
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